Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc. is poised for significant revenue growth, particularly with Giapreza, which addresses a substantial unmet need in septic shock management, expected to gain traction with updated treatment guidelines. Following the launch of Xacduro, sales projections indicate a robust upward trend, with anticipated revenue of approximately $21.1 million in 2024 and a notable run rate of $95.3 million by 2025. Additionally, the company's emphasis on expanding its portfolio, supported by strong sales growth and durable patent protection for its key products, reinforces Innoviva's commercial momentum and positive market outlook.

Bears say

Innoviva Inc faces significant challenges that underlie a negative outlook regarding its stock performance, primarily due to the severe health risks associated with multidrug-resistant pathogens, which could impede the successful commercialization of its products. The company confronts multiple risks that include potential failures in launching key products, increased competition from generic alternatives, and the possibility of partnership issues, all of which threaten revenue stability. Additionally, macroeconomic factors and investment value declines further exacerbate Innoviva's financial vulnerabilities, potentially hindering growth prospects and shareholder return.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Apr 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.